Skip to content

Study · Randomized controlled trial · n = 19 · 2004

3 results

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C

Diabetes/metabolism research and reviews1 Jan 2004Cited by 55 (Europe PMC)

PMID14737746 (opens in a new tab)DOI10.1002/dmrr.419 (opens in a new tab)PepBankPUB-14737746
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 2 diabetes, mealtime pramlintide reduced postprandial glucose excursions compared with insulin lispro plus placebo.

    In plain wordsIn type 2 diabetes, mealtime pramlintide reduced glucose rises after meals compared with insulin lispro plus placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose excursion with mealtime injection
    Study

    n = 19

    Comparator
    Insulin lispro plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Measurements

    Glucose excursion reduction
    81%
    mealtime injection versus placebo
    Incremental glucose AUC
    2 mmol/h/L
    pramlintide at 0 min
    Incremental glucose AUC
    10.4 mmol/h/L
    insulin lispro plus placebo

    Source sentences

    Summary
    When injected at 0 min, pramlintide reduced the postprandial glucose excursion by 81% compared to insulin lispro + placebo (incremental AUC(0-4 h) (mean +/- SE) 2.0 +/- 1.5 vs. 10.4 +/- 2.2 mmol/h/L, P<0.05).
    3 context sentences
    Summary · context
    In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 2 diabetes using insulin lispro underwent five consecutive mixed-meal tests.
    Summary · context
    In randomized order, subjects received subcutaneous injections of placebo at -15 min or 120-microg pramlintide at -15, 0, +15, or +30 min relative to the standardized breakfast after an overnight fast.
    Summary · context
    Insulin lispro was injected at 0 min at doses that were adjusted appropriately for both the content of the standardized meal and the anticipated effects of pramlintide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In type 2 diabetes, pramlintide before or after meals reduced glucose excursions versus placebo, less than mealtime injection.

    In plain wordsIn type 2 diabetes, pramlintide before or after meals reduced glucose rises versus placebo, less than mealtime injection.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose excursion at other injection times
    Study

    n = 19

    Comparator
    Insulin lispro plus placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Measurements

    Glucose AUC reduction
    42 to 73%
    injections at -15, +15 and +30 min

    Source sentences

    Summary
    When pramlintide was injected at -15, +15, and +30 min, the postprandial incremental glucose AUC(0-4 h) was also significantly reduced (P<0.05), but to a lesser extent (42 to 73%).
    3 context sentences
    Summary · context
    In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 2 diabetes using insulin lispro underwent five consecutive mixed-meal tests.
    Summary · context
    In randomized order, subjects received subcutaneous injections of placebo at -15 min or 120-microg pramlintide at -15, 0, +15, or +30 min relative to the standardized breakfast after an overnight fast.
    Summary · context
    Insulin lispro was injected at 0 min at doses that were adjusted appropriately for both the content of the standardized meal and the anticipated effects of pramlintide.
  3. 03HumanRandomized controlled trialSafety outcome

    In type 2 diabetes, no serious adverse events were reported with pramlintide treatment.

    In plain wordsIn type 2 diabetes, no serious adverse events were reported with pramlintide treatment.

    Peptide
    Pramlintide (Symlin)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 19

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 microg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Pramlintide treatment was well tolerated and no serious adverse events were reported.
    3 context sentences
    Summary · context
    In this randomized, single-blind, placebo-controlled, five-way crossover study, 19 subjects with type 2 diabetes using insulin lispro underwent five consecutive mixed-meal tests.
    Summary · context
    In randomized order, subjects received subcutaneous injections of placebo at -15 min or 120-microg pramlintide at -15, 0, +15, or +30 min relative to the standardized breakfast after an overnight fast.
    Summary · context
    Insulin lispro was injected at 0 min at doses that were adjusted appropriately for both the content of the standardized meal and the anticipated effects of pramlintide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.